Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00980057 · ClinicalTrials.gov registry record · NA
Adaptive Cardiac Resynchronization Therapy Study
A NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- NA
- Development phase
- 522
- Enrollment target
NCT00980057: Completed NA study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
NCT00980057 is a NA study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 522 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00980057, a NA study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- NA
- Development phase
- 522 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the AdaptivCRT algorithm is at least as good as manual echo based optimization in regard to patient outcomes and cardiac performance
Primary Outcome
Patients considered worsened if they died, were hospitalized with worsening heart failure (HF), crossed over to other arm, demonstrated worsening in New York Heart Association (NYHA) functional class, or reported moderately/markedly worse on 'patient global assessment' compared to before CRT implant. Patients are improved if they are not worsened and have an improved NYHA or reported moderately/markedly improved on the 'patient global assessment' compared to before CRT implant Global assessment
Interventions
- DEVICE Adaptive CRT (aCRT)
- DEVICE Echo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 522 participants |
| Start Date | 2009-10-01 |
| Est. Completion | 2012-03-08 |
| Phase | NA |
What the finished NCT00980057 record still lists
NCT00980057 is an interventional study that assigns participants to a tested intervention. The registered 522 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 2 interventions - of which Adaptive CRT (aCRT) is the first listed.
NCT00980057 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00980057 about?
NCT00980057 is a clinical study titled "Adaptive Cardiac Resynchronization Therapy Study". The purpose of this study is to demonstrate the AdaptivCRT algorithm is at least as good as manual echo based optimization in regard to patient outcomes and cardiac performance
What is the current status of trial NCT00980057?
This trial is currently completed. It is a NA study. The enrollment target is 522 participants. The study started on 2009-10-01. Estimated completion is 2012-03-08.
What interventions are being tested in trial NCT00980057?
The interventions under investigation include: Adaptive CRT (aCRT) (DEVICE), Echo (DEVICE).
Who is sponsoring clinical trial NCT00980057?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00980057's enrollment target sits among peer trials
522 189th of 2000 higher than 1,811 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06835686 · 522 participants · NA
Collaborative Multi-level Obesity Intervention Engaging Underserved Communities Trial
- NCT06894212 · 522 participants · Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
- NCT03526835 · 523 participants · Phase 1
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- NCT04580134 · 524 participants · Phase 4
CLOZAPINE Response in Biotype-1
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI